



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

ELI LILLY AND COMPANY

By KSR Rhodes

Date 9-22-03

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Suad Efendic)	
)	
Serial No.	:	09/834,229)	
)	Group Art Unit:
Filed	:	April 12, 2001)	1647
)	
For	:	Use of GLP-1 or Analogs)	
		in treatment of myocardial)	Examiner
		infarction)	C. Saoud
)	
Docket No.	:	X-10822A)	

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

SEP 29 2003

TECHNICAL 1622/2003

Sir:

Identification of Person Making This Disclaimer

I, Gregory A. Cox, am employed by Eli Lilly and Company, and I am an agent of record in the above-identified patent application. In that capacity, I am authorized to sign this disclaimer on behalf of Eli Lilly and Company.

Identity of Assignee

I hereby verify that the assignee owning all of the interest in this application is:

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285

09/26/2003 HBIZUNES 00000018 050840 09834229

01 FC:1814 110.00 DA

Serial No. 09/834,229

Recordal of Assignment in PTO

The assignment was recorded on September 26, 1997, Reel 8722, Frame 0640.

Extent of Interest

The extent of Eli Lilly and Company's interest is in the whole of this invention.

Disclaimer

I hereby disclaim the terminal part of any patent granted on this application, which would extend beyond the expiration date of:


United States Patent No. 5,705,483 and hereby agree that any patent granted on this application shall be enforceable only for and during such period that the legal title to the patent shall be the same as the legal title to United States Patent No. 5,705,483.

I do not disclaim any terminal part of any patent granted on this application prior to the expiration date of the full statutory term of United States Patent No. 5,705,483 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term other than as presently shortened by any terminal disclaimer.

Fee Payment

Please charge \$110.00, the fee set forth in 37 C.F.R. 1.20(d), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840 in the name of Eli Lilly and Company. Two copies of this disclaimer are enclosed.

Respectfully submitted,



Gregory A. Cox
Attorney for Applicant
Registration No. 47,504
Phone: 317-277-2620

Eli Lilly and Company
Patent Division/GAC
P.O. Box 6288
Indianapolis, Indiana 46206-6288

Sept. 22, 2003